Literature DB >> 16904154

Virus-like particles derived from major capsid protein VP1 of different polyomaviruses differ in their ability to induce maturation in human dendritic cells.

Alma Gedvilaite1, David C Dorn, Kestutis Sasnauskas, Gabriele Pecher, Aiste Bulavaite, Robert Lawatscheck, Juozas Staniulis, Tina Dalianis, Torbjörn Ramqvist, Günther Schönrich, Martin J Raftery, Rainer Ulrich.   

Abstract

As polyomavirus major capsid protein VP1-derived virus-like particles (VLPs) have been demonstrated to be highly immunogenic, we studied their interaction with human dendritic cells (hDCs). Exposure of hDCs to VLPs originating from murine (MPyV) or hamster polyomavirus (HaPyV) induced hDC maturation. In contrast, exposure of hDCs to VLPs derived from human polyomaviruses (BK and JC) and simian virus 40 (SV40) only marginally induced DC maturation. The hDCs stimulated by HaPyV- or MPyV-derived VLPs readily produced interleukin-12 and stimulated CD8-positive T-cell responses in vitro. The highest frequencies of activated T cells were again observed after pulsing with HaPyV- and MPyV-derived VLPs. Monocyte-derived hDCs both bound and internalized the various tested polyomavirus VP1-derived VLPs with different levels of efficiency, partially explaining their individual maturation potentials. In conclusion, our data suggest a high variability in uptake of polyomavirus-derived VLPs and potency to induce hDC maturation.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16904154     DOI: 10.1016/j.virol.2006.07.007

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  8 in total

1.  Generation of a tumor vaccine candidate based on conjugation of a MUC1 peptide to polyionic papillomavirus virus-like particles.

Authors:  Sharmila Pejawar-Gaddy; Yogendra Rajawat; Zoe Hilioti; Jia Xue; Daniel F Gaddy; Olivera J Finn; Raphael P Viscidi; Ioannis Bossis
Journal:  Cancer Immunol Immunother       Date:  2010-07-21       Impact factor: 6.968

Review 2.  BK Polyomavirus: Clinical Aspects, Immune Regulation, and Emerging Therapies.

Authors:  George R Ambalathingal; Ross S Francis; Mark J Smyth; Corey Smith; Rajiv Khanna
Journal:  Clin Microbiol Rev       Date:  2017-04       Impact factor: 26.132

3.  Chimeric calicivirus-like particles elicit specific immune responses in pigs.

Authors:  E Crisci; L Fraile; N Moreno; E Blanco; R Cabezón; C Costa; T Mussá; M Baratelli; P Martinez-Orellana; L Ganges; J Martínez; J Bárcena; M Montoya
Journal:  Vaccine       Date:  2012-02-03       Impact factor: 3.641

4.  Induction of insert-specific immune response in mice by hamster polyomavirus VP1 derived virus-like particles carrying LCMV GP33 CTL epitope.

Authors:  Egle Mazeike; Alma Gedvilaite; Ulrike Blohm
Journal:  Virus Res       Date:  2011-08-16       Impact factor: 3.303

Review 5.  Virus-like particles: the new frontier of vaccines for animal viral infections.

Authors:  Elisa Crisci; Juan Bárcena; María Montoya
Journal:  Vet Immunol Immunopathol       Date:  2012-06-01       Impact factor: 2.046

6.  Non-permissive human conventional CD1c+ dendritic cells enable trans-infection of human primary renal tubular epithelial cells and protect BK polyomavirus from neutralization.

Authors:  Mathieu Sikorski; Flora Coulon; Cécile Peltier; Cécile Braudeau; Alexandra Garcia; Matthieu Giraud; Karine Renaudin; Christine Kandel-Aznar; Steven Nedellec; Philippe Hulin; Julien Branchereau; Joëlle Véziers; Pauline Gaboriaud; Antoine Touzé; Julien Burlaud-Gaillard; Régis Josien; Dorian McIlroy; Céline Bressollette-Bodin; Franck Halary
Journal:  PLoS Pathog       Date:  2021-02-16       Impact factor: 6.823

Review 7.  Virus-like particle-based vaccines for animal viral infections.

Authors:  Elisa Crisci; Juan Bárcena; María Montoya
Journal:  Inmunologia       Date:  2012-10-26

Review 8.  Hamster Polyomavirus Research: Past, Present, and Future.

Authors:  Burkhard Jandrig; Hans Krause; Wolfgang Zimmermann; Emilija Vasiliunaite; Alma Gedvilaite; Rainer G Ulrich
Journal:  Viruses       Date:  2021-05-13       Impact factor: 5.048

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.